7-Dehydrocholesterol Reductase Activates the Hedgehog Pathway by Regulating Cholesterol to Promote the Development of Triple-Negative Breast Cancer.

IF 3.5 4区 医学 Q3 ONCOLOGY Current cancer drug targets Pub Date : 2025-01-01 DOI:10.2174/0115680096363566250119155918
Shuang Qiu, Yu Sun, Yuanyuan Liu, Jinyu Yang, Xin Chen, Di Wu, Li Li, Jianwei Sun
{"title":"7-Dehydrocholesterol Reductase Activates the Hedgehog Pathway by Regulating Cholesterol to Promote the Development of Triple-Negative Breast Cancer.","authors":"Shuang Qiu, Yu Sun, Yuanyuan Liu, Jinyu Yang, Xin Chen, Di Wu, Li Li, Jianwei Sun","doi":"10.2174/0115680096363566250119155918","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cholesterol has been shown to be a potential risk factor for the occurrence and progression of breast cancer. This study aimed to investigate the regulation of DHCR7 in cholesterol synthesis and its role in Hedgehog (Hh) signaling pathway activation, as well as its impact on the progression of triple-negative breast cancer (TNBC).</p><p><strong>Methods: </strong>We analyzed the gene expression data from the GSE76275 data set by bioinformatics analysis to determine the expression of cholesterol-related genes in TNBC. In the TNBC cell lines, including BT-549 and MDA-MB-231, RNA interference gene knockout was used to evaluate the functional impact of DHCR7. In addition, the SMO mutant (SMO<sup>V329F</sup>) with anti-cholesterol binding inhibition was introduced to determine its interaction with the pathway changes mediated by DHCR7. Cell proliferation, migration, and signaling pathway activation were assessed through Western blotting, CCK-8 assay, transwell migration assay, and qPCR.</p><p><strong>Results: </strong>DHCR7 expression was significantly elevated in TNBC tissues and cell lines, enhancing the Hh pathway activity through cholesterol modulation. Knocking down DHCR7 and the SMO<sup>V329F</sup> mutation both reduced the expression of Hedgehog-related proteins and inhibited cell proliferation and migration abilities. However, the SMO<sup>V329F</sup> mutation reversed the inhibitory effect of knocking down DHCR7 on TNBC cells.</p><p><strong>Conclusion: </strong>DHCR7 activates the Hedgehog pathway by regulating cholesterol to promote the development of TNBC. These findings provide insights into the regulatory roles of DHCR7 in cholesterol-related pathways and Hh signaling in TNBC cells, offering potential therapeutic targets for TNBC treatment.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":"780-794"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096363566250119155918","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cholesterol has been shown to be a potential risk factor for the occurrence and progression of breast cancer. This study aimed to investigate the regulation of DHCR7 in cholesterol synthesis and its role in Hedgehog (Hh) signaling pathway activation, as well as its impact on the progression of triple-negative breast cancer (TNBC).

Methods: We analyzed the gene expression data from the GSE76275 data set by bioinformatics analysis to determine the expression of cholesterol-related genes in TNBC. In the TNBC cell lines, including BT-549 and MDA-MB-231, RNA interference gene knockout was used to evaluate the functional impact of DHCR7. In addition, the SMO mutant (SMOV329F) with anti-cholesterol binding inhibition was introduced to determine its interaction with the pathway changes mediated by DHCR7. Cell proliferation, migration, and signaling pathway activation were assessed through Western blotting, CCK-8 assay, transwell migration assay, and qPCR.

Results: DHCR7 expression was significantly elevated in TNBC tissues and cell lines, enhancing the Hh pathway activity through cholesterol modulation. Knocking down DHCR7 and the SMOV329F mutation both reduced the expression of Hedgehog-related proteins and inhibited cell proliferation and migration abilities. However, the SMOV329F mutation reversed the inhibitory effect of knocking down DHCR7 on TNBC cells.

Conclusion: DHCR7 activates the Hedgehog pathway by regulating cholesterol to promote the development of TNBC. These findings provide insights into the regulatory roles of DHCR7 in cholesterol-related pathways and Hh signaling in TNBC cells, offering potential therapeutic targets for TNBC treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
7-脱氢胆固醇还原酶通过调节胆固醇激活Hedgehog通路促进三阴性乳腺癌的发展
背景:胆固醇已被证明是乳腺癌发生和发展的潜在危险因素。本研究旨在探讨DHCR7在胆固醇合成中的调控作用及其在Hedgehog (Hh)信号通路激活中的作用,以及对三阴性乳腺癌(TNBC)进展的影响。方法:采用生物信息学分析方法,对GSE76275数据集中的基因表达数据进行分析,确定三阴性乳腺癌中胆固醇相关基因的表达。在包括BT-549和MDA-MB-231在内的三阴性乳腺癌细胞系中,采用RNA干扰基因敲除来评估DHCR7的功能影响。此外,引入具有抗胆固醇结合抑制作用的SMO突变体(SMOV329F),以确定其与DHCR7介导的通路变化的相互作用。通过Western blotting、CCK-8实验、transwell迁移实验和qPCR评估细胞增殖、迁移和信号通路激活。结果:DHCR7在TNBC组织和细胞系中表达显著升高,通过胆固醇调节增强Hh通路活性。敲除DHCR7和SMOV329F突变均可降低刺猬相关蛋白的表达,抑制细胞增殖和迁移能力。然而,SMOV329F突变逆转了敲低DHCR7对TNBC细胞的抑制作用。结论:DHCR7通过调节胆固醇激活Hedgehog通路,促进TNBC的发展。这些发现提供了DHCR7在TNBC细胞中胆固醇相关通路和Hh信号传导中的调节作用,为TNBC治疗提供了潜在的治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current cancer drug targets
Current cancer drug targets 医学-肿瘤学
CiteScore
5.40
自引率
0.00%
发文量
105
审稿时长
1 months
期刊介绍: Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
期刊最新文献
Methyl-β-Cyclodextrin Enhances the Chemotherapeutic Efficacy of Paclitaxel in Breast Cancer Cells. NDUFA10: An Emerging Oncogenic Driver of Metastasis in Lung Adenocarcinoma. In Silico Multi-omics Analyses of Kinesin Family Member 15 in Pan-Cancer and Validation in Tissue Microarray. Comparative Analysis of Homologous Recombination Repair Status Across Gynecologic and Breast Cancers in Chinese Populations. Immunotherapy with Chemotherapy in Recurrent or Metastatic Maxillary Sinus Squamous Cell Carcinoma: A Real-world Study in China.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1